Transformation and Metastasis

Eva Gonzalez Suarez

CLINICAL RESEARCHERS
  • Maria Teresa Soler Monsó
  • Andrea Carolina Vethencourt Casado
CANCER
ONCOBELL

Scientific production

3

PAPERS

Average IF: 10,616

2 PUBLICATIONS IN FIRST DECILE

2 PUBLICATIONS IN FIRST QUARTILE

1 PUBLICATION IN OPEN ACCESS

Selected publications

  • Mateo,F;He,Z;Mei,L;de Garibay,GR;Herranz,C;García,N;Lorentzian,A et al, Modification of BRCA1-associated breast cancer risk by HMMR overexpression., Nat. Commun., 2022;13(1):1895-1895, doi:10.1038/s41467-022-29335-z
  • Stradella,A;Gargallo,P;Cejuela,M;Petit,A;Bosch Schips,J;Carbonell,P;Recalde,S et al, Genomic characterization and tumor evolution in paired samples of metaplastic breast carcinoma., Mod. Pathol., 2022;35(8):1066-1074, doi:10.1038/s41379-022-01017-7
  • Cejuela,M;Vethencourt,A;Pernas,S, Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer., Curr. Oncol. Rep. 2022;doi:10.1007/s11912-022-01339-4

Research highlights

PROJECTS

3 Ongoing competitive projects

1 Started clinical trial
1 Ongoing clinical trial
1 Ongoing non-competitive projects

PUBLISHED WORKS

1 thesis

NETWORKS

ENBDC
IABCR
EurOPDX
ASEICA
EACR

Selected projectes

  • 16CEE012. PLEIO-RANK:Pleiotropic treatment of cancer: RANK inhibitors targeting cancer stem cells and immunity. COMISSIÓ EUROPEA. Budget: 1999960,01. 2016-2023. PI: González Suárez, Eva.
  • 17PRV003. An open label biomarker pilot study of the antitumoral activity of denosumab in the pre- operative setting of early breast cancer. Amgen Inc. Budget: 517652. 2019-2023. PI: Eva Gonzalez Suarez.
  • 20FIS036. CONTRATOS RIO HORTEGA. Instituto de Salud Carlos III (ISCIII). Budget: 53732. 2020-2022. PI: González Suárez, Eva.
  • 21PSJ002. Estudio de biomarcadores de la actividad antitumoral del denosumab y su papel como modulador de la respuesta inmune en el cáncer de mama precoz: IO-D-BIOMARK. Fundación Grupo Español de Investigación en Cancer de Mama (GEICAM). Budget: 42000. 2021-2024. PI: Vethencourt CASADO, Andrea Carolina.
  • 2022-114-1. A Randomized Phase II Study to Evaluate the Incidence of Discontinuations due to Diarrhoea at 3 Cycles in patients with Earlystage HER2-positive (HER2+), Hormone Receptor-positive (HR+) Breast Cancer treated with Neratinib plus Loperamide prophylaxis versus Neratinib with Initial Dose Escalation plus PRN Loperamide prophylaxis versus Neratinib plus Loperamide plus Colesevelam prophylaxis. DIANER Study. Fundación Grupo Español de Investigación en Cancer de Mama (GEICAM). Budget: 20400. 2022- . PI: Vethencourt CASADO, Andrea Carolina.